Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Y. Kito, T. Yamada, T. Matsumoto, H. Yasui, K. Murata, A. Makiyama, H. Hara, E. Baba, K. Nishio, K. Yoshimura, S. Hironaka, K. Muro, K. Yamazaki

    Research output: Contribution to journalArticlepeer-review

    Original languageEnglish
    Pages (from-to)viii201
    JournalAnnals of oncology : official journal of the European Society for Medical Oncology
    Publication statusPublished - Oct 1 2018

    All Science Journal Classification (ASJC) codes

    • Hematology
    • Oncology

    Cite this